Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Gilead Sciences (GILD)

Gilead Sciences Reports Q3 2026 Financial Results and Raises Full-Year Guidance

Mixed Impact 4 of 5 earnings

Gilead Sciences announced its third quarter 2026 financial results, reporting a 13% increase in total product sales to $8.3 billion driven by growth in HIV and oncology products. The company also raised its full-year 2026 base business revenue guidance for the year, bringing total increases to $1.6 billion since the start of the year.

Key points

  • Total third quarter 2026 product sales increased 13% year-over-year to $8.3 billion.
  • GAAP diluted earnings per share was $1.94 for the third quarter of 2026 compared to $2.43 in the prior year period.
  • Full-year 2026 product sales guidance was raised to a range of $31.0 billion to $31.3 billion.
  • As of September 30, 2026, cash, cash equivalents and marketable debt securities totaled $6.4 billion.

The filing

CompanyGilead Sciences (GILD)
Form8-K, current report
Filed with the SECOct 29, 2026, 4:03 PM ET
Accession number0000882095-26-000037

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Oct 29, 2026, 5:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.